Keros Therapeutics, Inc. Insider Trading for February 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Keros Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Keros Therapeutics, Inc. for February 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 63.85 | 30 | 1,916 | 450,930 | 451 K to 450.9 K (-0.01 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 63.85 | 46 | 2,937 | 676,148 | 676.2 K to 676.1 K (-0.01 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 63.14 | 531 | 33,527 | 450,960 | 451.5 K to 451 K (-0.12 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 63.14 | 814 | 51,396 | 676,194 | 677 K to 676.2 K (-0.12 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 62.52 | 641 | 40,075 | 451,491 | 452.1 K to 451.5 K (-0.14 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 62.52 | 985 | 61,582 | 677,008 | 678 K to 677 K (-0.15 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 61.03 | 913 | 55,720 | 452,132 | 453 K to 452.1 K (-0.20 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 61.03 | 1,397 | 85,259 | 677,993 | 679.4 K to 678 K (-0.21 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 60.20 | 833 | 50,147 | 453,045 | 453.9 K to 453 K (-0.18 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 60.20 | 1,278 | 76,936 | 679,390 | 680.7 K to 679.4 K (-0.19 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 67.98 | 35 | 2,379 | 453,878 | 453.9 K to 453.9 K (-0.01 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 67.99 | 53 | 3,603 | 680,668 | 680.7 K to 680.7 K (-0.01 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 66.65 | 206 | 13,730 | 453,913 | 454.1 K to 453.9 K (-0.05 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 66.65 | 316 | 21,061 | 680,721 | 681 K to 680.7 K (-0.05 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 65.80 | 1,575 | 103,635 | 454,119 | 455.7 K to 454.1 K (-0.35 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 65.80 | 2,418 | 159,104 | 681,037 | 683.5 K to 681 K (-0.35 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 64.87 | 952 | 61,756 | 455,694 | 456.6 K to 455.7 K (-0.21 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 64.87 | 1,461 | 94,775 | 683,455 | 684.9 K to 683.5 K (-0.21 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 63.83 | 1,526 | 97,405 | 456,646 | 458.2 K to 456.6 K (-0.33 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 63.83 | 2,335 | 149,043 | 684,916 | 687.3 K to 684.9 K (-0.34 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 62.79 | 270 | 16,953 | 458,172 | 458.4 K to 458.2 K (-0.06 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Knowles Julius | Director | Sell | S | 62.79 | 414 | 25,995 | 687,251 | 687.7 K to 687.3 K (-0.06 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Option Exercise | M | 0.48 | 1,000 | 480 | 102,211 | |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 68.05 | 2 | 136 | 0 | 2 to 0 (-100.00 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 66.19 | 295 | 19,526 | 2 | 297 to 2 (-99.33 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 65.35 | 216 | 14,116 | 297 | 513 to 297 (-42.11 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 64.17 | 312 | 20,021 | 513 | 825 to 513 (-37.82 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Sell | S | 63.10 | 175 | 11,043 | 825 | 1,000 to 825 (-17.50 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Ordonez Claudia | Chief Medical Offic ... | Buy | M | 0.48 | 1,000 | 480 | 1,000 | 0 to 1,000 |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Option Exercise | M | 0.30 | 5,300 | 1,590 | 145,605 | |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 68.05 | 14 | 953 | 27,991 | 28 K to 28 K (-0.05 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 67.05 | 262 | 17,567 | 28,005 | 28.3 K to 28 K (-0.93 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 65.99 | 1,845 | 121,752 | 28,267 | 30.1 K to 28.3 K (-6.13 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 64.93 | 1,272 | 82,591 | 30,112 | 31.4 K to 30.1 K (-4.05 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 63.74 | 1,460 | 93,060 | 31,384 | 32.8 K to 31.4 K (-4.45 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Sell | S | 62.85 | 447 | 28,094 | 32,844 | 33.3 K to 32.8 K (-1.34 %) |
| Feb 16 2021 | KROS | Keros Therapeutics ... | Lachey Jennifer | Chief Scientific Of ... | Buy | M | 0.30 | 5,300 | 1,590 | 33,291 | 28 K to 33.3 K (+18.93 %) |